Published in J Cancer Res Clin Oncol on August 20, 2009
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol (2015) 0.81
Plasma concentrations of soluble IL-2 receptor α (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients. Diabetologia (2013) 0.80
Elevation of proinflammatory cytokines in patients with Aicardi-Goutières syndrome. Neurology (2013) 0.78
Monoclonal antibodies directed against chicken β2-microglobulin developed with a synthesized peptide. Monoclon Antib Immunodiagn Immunother (2013) 0.75
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol (2005) 1.86
Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma (2006) 1.65
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol (2007) 1.45
The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol (2002) 1.30
Strategies of tumor immune evasion. BioDrugs (2005) 1.26
Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers (2008) 1.20
Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood (1989) 1.19
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant (2006) 1.14
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09
Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med (2007) 1.07
Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer (2000) 1.05
Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res (2007) 1.04
Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer (2002) 1.03
Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol (2001) 1.02
Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs (2002) 1.02
Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori (2005) 1.01
Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol (2008) 0.98
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer (2008) 0.98
Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer (2008) 0.95
Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist (2008) 0.94
Quantitation of beta2-microglobulin and HLA on the surface of human cells. I. T and B lymphocytes and lymphoblasts. Scand J Immunol (1977) 0.94
The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen. Scand J Immunol (1994) 0.93
Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep (1999) 0.92
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer (2002) 0.92
Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol (1999) 0.92
Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol (2006) 0.90
Class I MHC molecules: assembly and antigen presentation. Immunol Rev (1999) 0.89
The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer (1990) 0.88
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood (2006) 0.87
The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica (2007) 0.87
Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol (2000) 0.87
Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer. Int J Clin Oncol (2002) 0.87
Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit (2001) 0.87
Soluble interleukin-2 receptor in childhood non-Hodgkin's lymphoma. Blood (1988) 0.86
Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood. Leukemia (1993) 0.86
Novel peptides secreted from human neuroblastoma: useful clinical tools? J Pediatr Surg (2006) 0.86
Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine (2006) 0.85
Serum beta 2-microglobulin and prognosis of patients with renal cell carcinoma. Acta Oncol (1996) 0.85
Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res (2001) 0.85
Turnover in humans of beta 2-microglobulin: the constant chain of HLA-antigens. Eur J Clin Invest (1980) 0.83
Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer (2007) 0.83
Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2000) 0.82
Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Otolaryngol (2009) 0.81
[Does beta-2 microglobulin measurement play role in diagnostics of childhood malignancies?]. Wiad Lek (2004) 0.81
Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer (1999) 0.80
Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev (2005) 0.80
Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm (2005) 0.80
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer (2009) 0.80
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol (2008) 0.80
The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol (2000) 0.79
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat (2000) 0.79
Serum level of soluble interleukin-2 receptor alpha correlates with the clinical course and activity of Wilms' tumour and soft tissue sarcomas in children. Biomarkers (2007) 0.79
Beta-2-microglobulin as a tumor marker in solid malignancies. Oncology (1988) 0.78
Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders. Eur J Haematol (1999) 0.78
[Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer]. Med Wieku Rozwoj (2005) 0.78
Prognostic value of clinicopathologic characteristics including neuroectodermal differentiation in osseous Ewing's sarcoma family of tumors in children. Tumori (1999) 0.78
A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing's tumor into low and high risk. Ann Oncol (2003) 0.77
Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients. Int J Biol Markers (1995) 0.77
Soluble histocompatibility antigen class I in breast cancer patients in relation to tumor burden. Cancer (1991) 0.76
Upregulation of IFN-gamma and soluble interleukin-2 receptor release and altered serum cortisol and prolactin concentration during general anesthesia. J Interferon Cytokine Res (2001) 0.76
The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer. Jpn J Clin Oncol (1998) 0.76
Soluble immunological parameters and early prognosis of renal cell cancer patients. J Exp Clin Cancer Res (2001) 0.76
Multiple myeloma. Clin J Am Soc Nephrol (2006) 0.76
The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation. Cancer Immunol Immunother (2002) 0.76
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant (2007) 0.76
Serum lactate dehydrogenase as a prognostic marker of childhood acute lymphoblastic leukemia. Mymensingh Med J (2008) 0.75
Analysis of serum lactate dehydrogenase and its isozymes during administration of granulocyte colony-stimulating factor in children. Int J Hematol (2000) 0.75
Prognostic significance of elevated lactate dehydrogenase and creatine kinase in patients with rhabdomyosarcoma. Med Pediatr Oncol (2003) 0.75
beta2-microglobulin in patients with urothelial cancer. World J Urol (1999) 0.75
Serum soluble interleukin 2 receptor alpha and soluble CD8 levels in patients with gynecological malignancies undergoing radiotherapy. Arch Immunol Ther Exp (Warsz) (1996) 0.75
[Diagnostic and prognostic significance of serum soluble interleukin 2 receptor in children with malignancies]. Wiad Lek (2006) 0.75
Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms. Anticancer Res (1996) 0.75
Serum beta 2-microglobulin in chronic diseases of the pancreas. Int J Pancreatol (1995) 0.75
Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol (2007) 0.75
Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care (2012) 1.52
Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia--an overview of causative factors and possible therapeutic options. Childs Nerv Syst (2009) 1.42
Malignant germ cell tumors associated with Swyer syndrome. Pediatr Blood Cancer (2010) 1.39
Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene. Pediatr Blood Cancer (2009) 1.38
The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract (2007) 1.10
Pancreatoblastoma: a report from the European cooperative study group for paediatric rare tumours (EXPeRT). Eur J Cancer (2011) 1.00
Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm (2007) 1.00
Difficulties or mistakes in diagnosing type 1 diabetes in children?--demographic factors influencing delayed diagnosis. Pediatr Diabetes (2009) 1.00
Childhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases. Clin Exp Metastasis (2010) 0.96
[Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group]. Przegl Lek (2010) 0.92
Difficulties or mistakes in diagnosing type 1 diabetes mellitus in children? The consequences of delayed diagnosis. Pediatr Endocrinol Diabetes Metab (2008) 0.92
Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2007) 0.87
The activity of N-acetyl-beta-D-glucosaminidase and tumor necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children. Clin Biochem (2006) 0.84
Haemophilia A associated with Down's syndrome. Ann Hematol (2012) 0.83
[Recombinant erythropoietins--an alternative therapy to red cell blood transfusions in infants with hereditary spherocytosis]. Przegl Lek (2002) 0.82
Glomerular filtration rate and prevalence of chronic kidney disease in Wilms' tumour survivors. Pediatr Nephrol (2011) 0.82
[Selected immunologic and biochemical risk factors of the retinopathy and nephropathy development in children with diabetes mellitus type 1]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw (2006) 0.81
[Characteristics of extracranial malignant germ cell tumours in two age groups of children (0-10 and 10-18 years). Multicentre experiences]. Med Wieku Rozwoj (2011) 0.81
[Does beta-2 microglobulin measurement play role in diagnostics of childhood malignancies?]. Wiad Lek (2004) 0.81
Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol J Pathol (2010) 0.81
Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy. Childs Nerv Syst (2010) 0.80
[Interleukin-12, vascular endothelial growth factor and tumor necrosis factor-alpha in the process of neoangiogenesis of diabetic retinopathy in children]. Klin Oczna (2007) 0.80
Serum and urinary cytokine homeostasis and renal tubular function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab (2006) 0.79
[The health state evaluation in persons after therapy of Hodgkin's disease in childhood: report of the Polish Pediatric Leukemia/Lymphoma Study Group]. Przegl Lek (2006) 0.79
EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol (2010) 0.79
Prognostic significance of HER2 expression in neuroblastic tumors. Mod Pathol (2010) 0.79
Systemic mastocytosis in children - therapeutic problems. Med Wieku Rozwoj (2013) 0.79
Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res (2011) 0.79
Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res (2009) 0.79
Association between intestinal and antioxidant barriers in children with cancer. Acta Biochim Pol (2012) 0.78
[Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer]. Med Wieku Rozwoj (2005) 0.78
Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia. Folia Histochem Cytobiol (2012) 0.78
Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia. J Appl Genet (2003) 0.78
Immunohistochemical expression of procaspase-3 and its clinical significance in childhood non-Hodgkin lymphomas. Pediatr Dev Pathol (2010) 0.78
Thymic carcinoma in children: a report from the Polish Pediatric Rare Tumors Study. Pediatr Blood Cancer (2010) 0.78
[Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results]. Przegl Lek (2010) 0.78
[Analysis of microvascular density and the expression of vascular-endothelial growth factor (VEGF) and its membrane receptor Flk-1 in neuroblastoma]. Med Wieku Rozwoj (2007) 0.77
[Advances in the treatment of children with high risk acute lymphoblastic leukemia (ALL) treated with modified "NEW YORK" protocols between 1987 and 2002]. Przegl Lek (2003) 0.77
Serum IL-10 and IL-12 levels reflect the response to chemotherapy but are influenced by G-CSF therapy and sepsis in children with soft tissue sarcomas. Postepy Hig Med Dosw (Online) (2013) 0.77
The antioxidant status and response to therapy in children with soft tissue sarcomas and neuroblastoma. Pediatr Blood Cancer (2011) 0.77
c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients. BMC Cancer (2009) 0.77
Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: preliminary report. Acta Biochim Pol (2002) 0.77
[Results of immunosuppressive therapy in children with severe aplastic anaemia. Report by the Polish Paediatric Leukaemia and Lymphoma Study Group]. Med Wieku Rozwoj (2007) 0.77
The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res (2009) 0.77
Deregulated systemic IL-10/IL-12 balance in advanced and poor prognosis paediatric soft tissue sarcomas. Biomarkers (2013) 0.77
[Higher percentages of T regulatory cells in children at risk for developing type 1 diabetes mellitus]. Pediatr Endocrinol Diabetes Metab (2010) 0.77
Ischemia-modified albumin as a biochemical marker in children with neuroblastoma and soft tissue sarcomas. J Clin Lab Anal (2011) 0.77
Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. J Pharm Biomed Anal (2012) 0.76
Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome--clinical and pathological characteristics. Folia Neuropathol (2008) 0.76
Clinicopathological considerations on angiogenic potential in neuroblastoma Schwannian stroma - poor tumours. Folia Neuropathol (2007) 0.76
The effect of growth hormone treatment on serum bone alkaline phosphatase in growth hormone deficient children. Pediatr Endocrinol Diabetes Metab (2008) 0.76
Renal function and low-molecular-weight proteins (cystatin C, β2-microglobulin, neutrophil gelatinase-associated lipocalin) in child and young adult cancer survivors. J Pediatr Hematol Oncol (2012) 0.75
Coexistent neuroblastoma and histiocytosis? Med Pediatr Oncol (2003) 0.75
Parameters of antioxidant barrier in different histopathologic types of pediatric cancers. Contemp Oncol (Pozn) (2012) 0.75
Sarcomas in children with neurofibromatosis type 1-poor prognosis despite aggressive combined therapy in four patients treated in a single oncological institution. Childs Nerv Syst (2007) 0.75
[Acute renal failure in paediatric oncological disease]. Med Wieku Rozwoj (2008) 0.75
Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report. J Med Case Rep (2012) 0.75
[Efficacy of idarubicin in the treatment of childhood acute non-lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group]. Przegl Lek (2003) 0.75
[Two cases of congenital toxoplasmosis with a central nervous system damage--delayed diagnosis]. Ginekol Pol (2002) 0.75
[Can children with Hodgkin's disease be treated with chemotherapy only?]. Przegl Lek (2010) 0.75
[Interleukin 2 receptor--the structure, function and clinical significance in malignant diseases of adults and children]. Postepy Hig Med Dosw (2003) 0.75
When biopsy of the tumour is necessary to diagnose tuberculosis. J Paediatr Child Health (2011) 0.75
[Sudden death caused by myocarditis in a 14-year old boy with type I diabetes]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw (2004) 0.75
Factors predicting survival in childhood malignant and intermediate vascular tumors : retrospective analysis of the Polish and German cooperative paediatric soft tissue sarcoma study groups and review of the literature. Ann Surg Oncol (2010) 0.75
Methemoglobinemia in postchemotherapy stomatitis topical treatment: 2 pediatric cases. J Pediatr Hematol Oncol (2012) 0.75
[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)]. Przegl Lek (2010) 0.75
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia. Acta Biochim Pol (2002) 0.75
[Anhydrotic ectodermal dysplasia as cause of recurrent hyperthermia in a 5 month old infant]. Przegl Lek (2004) 0.75
[Bilateral Wilms' tumour. Results of treatment in 29 children]. Med Wieku Rozwoj (2004) 0.75
Renal function and solitary kidney disease: Wilms tumour survivors versus patients with unilateral renal agenesis. Kidney Blood Press Res (2011) 0.75
In memoriam Professor Andrzej Roszkiewicz (27.05.1941-12.09.2014). Pol J Pathol (2015) 0.75
Analysis of the impact of environmental and social factors, with a particular emphasis on education, on the level of metabolic control in type 1 diabetes in children. Endokrynol Pol (2012) 0.75
[Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications]. Przegl Lek (2004) 0.75
[Influence of age on treatment results in children and adolescents with Hodgkin's disease]. Przegl Lek (2004) 0.75
[Progress in the treatment of non-Hodgkin's lymphoma (NHL) in children. The report of Polish Pediatric Leukaemia/lymphoma Study Group (PPLLSG)]. Przegl Lek (2004) 0.75
[Implementation of the unified model of presenting cancer diagnosis in Polish pediatric onco-hematology centers]. Przegl Lek (2004) 0.75
[Evaluation of systolic and diastolic function of the left ventricle in children with acute lymphoblastic leukaemia before treatment]. Przegl Lek (2004) 0.75
Does antineoplasm treatment decrease the glomerular filtration rate in children? Kidney Blood Press Res (2009) 0.75
[Nephroblastoma in children aged less than 6 months at diagnosis]. Med Wieku Rozwoj (2004) 0.75
[LCHAD (long-chain 3-hydroxyacyl-CoA dehydrogenase) deficiency as a cause of sudden death of a three months old infant]. Med Wieku Rozwoj (2003) 0.75
Cystic adult-type granulosa cell tumor in a 7-year-old girl with precocious pseudopuberty. Pediatr Int (2012) 0.75
[Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group]. Przegl Lek (2004) 0.75
[Budd-Chiari syndrome in 16 year old girl with essential thrombocytosis]. Med Wieku Rozwoj (2011) 0.75
In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report. Acta Biochim Pol (2002) 0.75